Skip Navigation



European Heart Journal Advance Access published online on February 5, 2007
European Heart Journal, doi:10.1093/eurheartj/ehl487
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/4/515    most recent
ehl487v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Agewall, S.
Right arrow Articles by Atar, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agewall, S.
Right arrow Articles by Atar, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Levosimendan: Perpetuum mobile?

Stefan Agewall

Division of Cardiology
Aker University Hospital and Faculty of Medicine
University of Oslo
0514 Oslo
Norway
Tel: +47 22 89 46 55
Fax: +47 22 89 42 59
E-mail address: stefan.agewall@medisin.uio.no

Dan Atar

Division of Cardiology
Aker University Hospital and Faculty of Medicine
University of Oslo
0514 Oslo
Norway

The first 10% of the full text of this article appears below.

We read with great interest the well-written review about levosimendan by De Luca et al.1 Levosimendan is certainly an interesting . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?